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Compelling biological and epidemiological evidences point to a key role of genetic variants of the TERT and TERC genes in can-
cer development. We analyzed the genetic variability of these two gene regions using samples of 2,267 multiple myeloma
(MM) cases and 2,796 healthy controls. We found that a TERT variant, rs2242652, is associated with reduced MM susceptibil-
ity (OR50.81; 95% CI: 0.72–0.92; p50.001). In addition we measured the leukocyte telomere length (LTL) in a subgroup of
140 cases who were chemotherapy-free at the time of blood donation and 468 controls, and found that MM patients had lon-
ger telomeres compared to controls (OR51.19; 95% CI: 0.63–2.24; ptrend50.01 comparing the quartile with the longest LTL
versus the shortest LTL). Our data suggest the hypothesis of decreased disease risk by genetic variants that reduce the effi-
ciency of the telomerase complex. This reduced efficiency leads to shorter telomere ends, which in turn may also be a marker
of decreased MM risk.
Multiple myeloma (MM) is the second most common hemato-
logical cancer and it arises from a single clone of malignant
plasma cells (PCs) in the bone marrow.1 In the most advanced
stages of the disease, malignant PCs can subsequently migrate
in extra-medullary districts. The mean age at diagnosis is usu-
ally around 60 years,1 while the worldwide incidence of this
neoplasm is around 1.5/100,000 new cases (age-standardized
ratio). In Europe the incidence is slightly higher, with 4.6/
100,000 and 3.2/100,000 new cases, respectively in men and
women. Risk factors for MM have been reviewed in Martino
et al.2 MM risk is clearly related to age, gender, ethnicity and
the presence of pre-malignant conditions such as MGUS. There
are epidemiological evidences supporting an increased risk of
MM among obese people and for those who have a low intake
either of ﬁsh or vegetables. Other suggested risk factors are
autoimmune diseases, viral infections, exposures to pesticides,
organic solvents, hairdresser’s products, smoking and alcohol
consumption. However the evidences are largely inconsistent.
Multiple lines of evidence suggest that genetic factors are
involved in MM pathogenesis.3,4 Several risk loci have been
proposed and a few have been identiﬁed through genome-
wide association studies (GWAS).2,5–11
The genetic variability of the telomerase reverse transcrip-
tase (TERT) and the telomerase RNA component (TERC)
gene regions could play a role in MM etiology for two rea-
sons: ﬁrst the two genes are responsible for crucial cellular
processes, namely telomere homeostasis, second their poly-
morphic variants have been found to be associated with mul-
tiple cancer types and other human phenotypes.12–24
TERT and TERC constitute the telomerase complex,25
whose correct functioning is fundamental for the accurate de
novo synthesis of telomeric ends. Even moderate changes in
TERT and TERC activity could profoundly affect telomere
homeostasis.26,27 Telomeres are highly specialized structures
that have a key role in various cellular processes such as
chromosomal stability and cell growth28–30 and in the proper
segregation of chromosomes to daughter cells.31 There is
overwhelming evidence suggesting telomere dysfunction,
mediated by telomerase activation, as a driving force in can-
cer development.26,32,33
TERT is a pleiotropic gene with several regulatory functions
other than catalyzing the synthesis of the telomeric ends,
including transcriptional regulation, subtelomeric silencing and
stem cell mobilization.30 It is not, therefore, surprising that it
harbors multiple variants associated with risk of different dis-
eases and in particular with various cancer types. For example
the rs2736100 SNP is associated with glioma, testicular and
lung cancer,16,18,20 while rs401681 is associated with lung, blad-
der and pancreatic cancer,17,19,21 rs10069690 with estrogen
receptor-negative breast cancer12,13 and rs2242652 with breast,
prostate and ovarian cancer.12,14,15 In addition, TERT polymor-
phisms are associated with other human phenotypes such as
pulmonary ﬁbrosis and PSA levels.22–24,34
A very recent GWAS has reported the association of
rs10936599 with increased risk of MM.7 This polymorphism
lies in 3q26.2, in a linkage disequilibrium (LD) region that
includes also the TERC gene. Clearly this ﬁnding further
increases the a priori hypothesis of the involvement of the
two genes in the disease.
Moreover polymorphic variants in both TERT and TERC
have been consistently associated with telomere length meas-
ured in leukocytes (LTL),35,36 which in turn is a putative
What’s new?
A critical element of cancer cell immortality is the maintenance of telomere length, a process that is influenced in part by
genetic variations in telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC). At the TERT locus in par-
ticular, certain variations are linked with either increased or decreased risk of a variety of malignancies. In the present study,
a variant of TERT known as rs2242652 was associated with reduced risk of multiple myeloma. Compared with controls,
patients with multiple myeloma were found to possess longer telomeres, suggesting an association between increased telo-
mere length and increased multiple myeloma risk.
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marker for cancer incidence and progression. In the last years
telomere length (TL) has been intensively studied in relation
to risk and survival of various cancer types, including hema-
tological ones.5,26,37,38 In particular in a very recent study
performed within the European prospective investigation on
cancer (EPIC), Hosnijeh et al.39 have shown that longer telo-
meres are associated with increased risk of MM. In most epi-
demiological studies TL is measured in DNA from peripheral
blood and used as a proxy for TL in other tissues. Whether
LTL reﬂects TL of other tissues is a matter of debate. Never-
theless, it has been shown that LTL correlates strongly with
TL in hematopoietic stem cells and hematopoietic progenitor
cells both in newborn and adults.40 In addition, the inter-cell
type variability is remarkably lower than the inter-individual
variability of LTL.40 Therefore, at least for the hematopoietic
cell lineages, it is reasonable to assume that LTL is an accu-
rate proxy of TL in other cell subtypes.
Thus there is compelling biological and epidemiological
evidence that point to a key importance of the TERT and
TERC genetic variants in cancer development, either as medi-
ators of TL, or through other not yet elucidated mechanisms.
Detailed genetic analysis of the TERT region has been per-
formed for some solid tumors,15 but no such effort has been
done in hematologic cancers.
Following these leads we have performed an in-depth
analysis of the genetic variability of the two regions. We have
used, in a two-phase study, biological material of 2,267 MM
cases and 2,796 healthy controls in the context of the Heidel-
berg Multiple Myeloma Group, the ESTHER cohort and the
International Multiple Myeloma rESEarch (IMMEnSE) con-
sortium. In addition we have also measured LTL in 140 MM
cases and 468 controls, in order to investigate, for the ﬁrst
time in a retrospective study of MM, if LTL is a susceptibility
marker for the disease. This effort is of particular importance
because it can link the genetic variability (the TERC and
TERT SNPs) and an intermediate phenotype (telomere
length) to the disease.
Material and Methods
Study populations and study design
We used three populations: the Heidelberg MM Group, the
ESTHER cohort and the IMMEnSE consortium. The ﬁrst
two studies were used as discovery set (phase I), respectively
using German MM patients from the Heidelberg MM Group
and German healthy controls from the ESTHER study. The
IMMEnSE consortium population has been used as a replica-
tion set (phase II) of the most signiﬁcant associations found
in phase I.
The Heidelberg MM Group patients comprised 585 cases
collected by the University Hospital in Heidelberg (Southwest
of Germany). In the ESTHER study 9,953 participants were
recruited in a 2-year span between July 2000 and December
2002 in Saarland (a state in Southwest Germany). The partic-
ipants were aged 50–75 years at enrollment (mean5 62.1;
SD5 6.6). Participants were recruited by their general practi-
tioners during a general health check-up. Eligible subjects
who accepted to participate in the study completed a ques-
tionnaire and provided a blood sample. In this study, a sub-
sample of 902 ESTHER subjects was used in the analysis of
the discovery phase.
The second phase of the study was conducted in the con-
text of the International Multiple Myeloma rESEarch
(IMMEnSE) consortium.2 The IMMEnSE study population
used for this study consisted of 1682 MM cases and 1894
controls recruited from seven different European countries.
Brieﬂy, cases were deﬁned by a conﬁrmed diagnosis of MM
according to the International Myeloma Working Group
(IMWG) criteria.41 Different region-speciﬁc subpopulations
of controls were selected among the general population as
well as among hospitalized subjects with different diagnoses
excluding cancer. Written informed consent was obtained
from each participant.
Relevant information on the study population is given in
Table 1.
SNP selection
The common genetic variability of the TERT gene regions
was investigated following a tagging approach and adding to
the selection SNPs previously shown to be associated with
cancer risk or telomere length. All SNPs within the region of
TERT/CLPTM1L (chr5:1277490–1377121, NCBI36/hg18)
with a minor allele frequency (MAF) >5% in Caucasians
(International HapMapProject, version 28; http://www.hap-
map.org) were included. Tagging SNPs were selected with the
Table 1. Description of the study population
Cases Controls Total
Geographic origin
Germany1 585 902 1,487
Italy2 258 237 495
Portugal2 68 99 167
Spain2 319 427 746
France2 127 191 318
Hungary2 159 105 264
Poland2 433 320 753
Denmark2 318 515 833
Total 2,267 2,796 5,063
Gender
Males 52% 49%
Females 48% 51%
Median age (25–75% percentiles)3
IMMEnSE 61 (54–68) 55 (44–65)
Germany2 56 (50–61) 61 (56–66)
1Cases from the Heidelberg MM Group, controls from the ESTHER
cohort (phase I).
2Subjects from the IMMEnSE consortium (phase II).
3Age at diagnosis for cases, age at recruitment for controls.
E
pi
de
m
io
lo
gy
Campa et al. E353
Int. J. Cancer: 136, E351–E358 (2015) VC 2014 UICC
use of the Haploview Tagger Program (http://www.broad.mit.
edu/mpg/haploview/; http://www.broad.mit.edu/mpg/tagger/),
using pairwise tagging with a minimum r2 of 0.8. We selected
additional SNPs signiﬁcantly associated at a genome-wide
level with cancer risk or with telomere length.12,15 For the
TERC gene we selected SNPs that have been previously asso-
ciated with telomere length or cancer risk and that reside in
chr3:170974797–170984874 (NCBI36/hg18).35,36,42 The ﬁnal
selection consisted of 29 SNPs, 22 in the TERT region and
7 in TERC.
Genotyping
Genomic DNA was extracted from peripheral blood and was
stored frozen at 220C. Genotyping was carried out at the
German Cancer Research Center (DKFZ) in Heidelberg using
TaqMan (ABI, Applied Biosystems, Foster City, CA) and
KASPar (LGC Genomics/KBioscence, Hoddesdon, UK) tech-
nologies, according to the protocol speciﬁed by the manufac-
turers and using respectively as master mixes the HOT
FIREPol (Solis Biodyne, Tartu, Estonia) and the KASPar
indirect assay reagent (LGC Genomics/KBioscence). The
order of DNAs from cases and controls was randomized on
384 well plates in order to ensure that a similar number of
cases and controls were analyzed simultaneously in the same
plate. For quality control purpose, duplicates of 10% of the
samples were interspersed throughout the plates. PCR reac-
tions were performed using a Hydrocycler instrument (LGC
Genomics/KBioscence) and the GeneAmpVR PCR System
(Applied Biosystems).
PCR plates were read on a ViiA7 real time instrument
(Applied Biosystems). The ViiA7 RUO Software, version
1.2.2 (Applied Biosystems) was used to determine the
genotypes.
Leukocyte telomere length measurement
Genomic DNA to measure telomere length was isolated from
cases and controls. For the cases the starting material for
DNA extraction was mononuclear cells separated from
peripheral blood while for the controls it was whole blood.
The average LTL was estimated in 585 cases from the Heidel-
berg MM group and a subsample of 468 randomly selected
controls from the ESTHER cohort. LTL was measured by
real-time PCR quantitative analysis (qPCR), measuring the
number of copies of telomeric repeats compared to a single
copy gene (RLP0), used as a quantitative control.43 Two sepa-
rate plates were used for PCR reactions: one contained pri-
mers speciﬁcally amplifying the telomeres (T), while the
other primers amplify a single copy gene (S). In addition, for
each plate a standard was prepared, by using a reference
DNA sample diluted in series, in order to produce ﬁve con-
centrations of DNA (range: 0.468–30 ng ml21). Each PCR
well contained 10 ng of DNA, 10 ll of mix containing the
primers speciﬁc for each plate T and S, PCR reagents and
SYBR green dye for ﬂuorescence detection. Finally, the rela-
tive length of telomeres (T) compared with the control gene
(S) was calculated as the ratio T/S. All the samples were ana-
lyzed in triplicate. For each measurement the mean of the
two closest values out of three was used. Supporting Informa-
tion Table 4 includes primer sequences used for the ampliﬁ-
cation of T and S, and details on the PCR ampliﬁcation
protocols.
Statistical analysis
The Hardy–Weinberg equilibrium (HWE) was tested in
controls for each polymorphism. In the ﬁrst phase we used
585 cases and 902 healthy controls of German origin to per-
form an unconditional logistic regression to assess the main
effects of the 29 selected genetic polymorphisms on MM
risk using a co-dominant and a dominant inheritance
model, calculating odds ratio (OR) and conﬁdence intervals
(CI). For each SNP the more common allele in the controls
was assigned as the reference category. All analyses were
adjusted for age (continuous), gender and region of origin.
Given the strong a priori probability to ﬁnd a signiﬁcant
association, all SNPs showing association with MM risk
with p< 0.15 were genotyped in an additional set of
1,682 MM cases and 1,894 controls recruited from the
IMMEnSE consortium. This selection resulted in eight SNPs
in TERT and one in TERC. In addition, SNP rs10936599
was added to phase two due to the association with MM
risk reported in a recent GWAS. The obtained genotyping
data were pooled with the ones obtained from phase one of
the study and an unconditional logistic regression using the
same criteria as described above was carried out. The signif-
icance threshold of the ﬁnal analysis was adjusted, taking
into account the large number of tests carried out. We used
a modiﬁed Bonferroni adjustment that takes into account
the effective number of independent variables tested in the
model. Because SNPs that are in linkage disequilibrium
reﬂect at least partially the same information, to take into
account the possibility of residual LD between the SNPs
selected in this study, for each locus we calculated the effec-
tive number of independent SNPs, (which is called Meff,),
using the SNP Spectral Decomposition approach (simpleM
method).44 We obtained a study-wide Meff value, by adding
up the individual gene Meff. The study-wise Meff obtained
was 18. Thus, the threshold for statistical signiﬁcance was
0.0028 (0.05/18). For SNP rs10936599 we also conducted a
meta-analysis with the results of the study by Chubb et al.7
reaching a total sample size of 6,112 MM cases and 12,905
healthy controls. Finally we also performed a meta-analysis
with the results of Hosnijeh et al.39 to better determine the
effect of LTL and MM risk.
Unconditional logistic regression was used to obtain the
OR and 95% CI for the strength of the association between
LTL and risk of MM. LTL was analyzed as a categorical vari-
able, using quartiles according to its distribution in control
subjects, with the lowest quartile as the referent. All the anal-
yses were conducted with STATA software (StataCorp, Col-
lege Station, TX).
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Bioinformatic analysis
We used several bioinformatic tools to assess possible func-
tional relevance of rs2242652 that showed the most signiﬁ-
cant association with risk of MM. RegulomeDB (http://
regulome.stanford.edu/)45 and HaploReg v2B46 were used to
identify the regulatory potential of the region nearby the
SNP. Genevar (http://www.sanger.ac.uk/resources/software/
genevar/)47 and GTex (http://commonfund.nih.gov/GTEx/
index) were used to identify potential associations between
the SNP and expression levels of nearby genes (eQTL).
Results
All the analyzed SNPs were in HWE in controls. The geno-
typing concordance rate between duplicate quality controls
was higher than 99% and the average SNP call rate was
98.37%.
SNP main effect
We performed a two step analysis analyzing 29 SNPs in a
discovery phase and replicating the best associations (9
SNPs that showed association with MM risk with p< 0.15
in the ﬁrst phase) in a larger sample size, for a total of
2,267 MM cases and 2,796 healthy controls. In addition a
susceptibility locus (SNP rs10936599) that lies in the TERC
region and was recently reported in a GWAS on MM risk7
was added to the second phase. Results of the ﬁrst phase
are reported in Supporting Information Tables 1 and 2,
while results of the joint analysis of phase 1 and 2 are
reported in Table 2. Supporting Information Table 7 reports
results of SNP and MM risk analysis stratiﬁed by country.
We found that 1 SNP was associated with MM risk consid-
ering the threshold for statistical signiﬁcance to be 0.0028
and a second variant was very close to statistical signiﬁ-
cance. The most signiﬁcant association was between the
minor allele of the TERT polymorphic variant rs2242652
and a decreased risk of MM (ORdominant5 0.81; 95% CI
0.72–0.92; p5 0.001). The other association was between
the TERC SNP rs12696304 and decreased risk of MM
(ORdominant5 0.83; 95% CI 0.74–0.94; p5 0.003). In addi-
tion we found one polymorphic variant that was associated
with MM risk at the conventional 0.05 threshold. Speciﬁ-
cally the TERT SNP rs10069690 was associated with
decreased risk of MM (ORdominant5 0.86; CI 0.75–0.99;
p5 0.03). However this SNP is in linkage disequilibrium
with rs2242652 (r25 0.82 in 1000G) and therefore they
reﬂect the same association. Finally, rs10936599 did not
show a signiﬁcant association with MM risk in the ﬁrst
phase of the study (Supporting Information Table 2), but
the association was observed in the IMMenSE population
(ORdominant5 0.83; 95% CI 0.71–0.99; p5 0.037) and it
reached study-wide statistical signiﬁcance in the joint analy-
sis (ORdominant5 0.82; 95% CI 0.72–0.93; p5 0.002). The
two polymorphisms in the TERC region are in strong LD
(r25 0.82), indicating that the two associations found are
not independent and represent the same locus.Ta
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Meta-analysis
For SNP rs10936599 we also performed a meta-analysis
between our results and those from Chubb et al.,7 including
a total of 6,112 MM cases and 12,905 healthy controls. For
the meta-analysis all the cases from the Heidelberg MM
group were excluded due to the partial overlap with the pub-
lication by Chubb. The results are conclusive indicating a
highly statistically signiﬁcant protective effect of the minor
allele of the SNP (OR5 0.80; 95% CI 0.76–0.85; p5 4.2 3
10214).
Effect of SNPs on LTL
We also attempted to correlate the selected SNPs with LTL
and we found that the minor alleles of the rs10936599 and
rs12696304 SNPs were associated, at the conventional thresh-
old of p< 0.05, with shorter telomeres (beta520.093;
p5 0.026; and beta520.075; p5 0.031, respectively). In
addition we observed that several SNPs reported in the litera-
ture to be associated with LTL, such as rs7726159, rs2736100
and rs7705526 showed a similar effect in our study, although
they did not reach statistical signiﬁcance. The complete
results for each SNP are shown in Supporting Information
Table 5.
LTL and MM risk
We calculated crude and adjusted (gender and age) OR. Che-
motherapeutic treatment and sample handling could modify
telomere length and therefore we considered as reliable only
the cases (N5 140) who were chemotherapy-free at the time
of blood drawing and whose samples were handled homoge-
neously in terms of time from blood collection to DNA isola-
tion and DNA extraction method. We found a weak
association of longer TL with increased risk of MM
(ptrend5 0.01). The complete results are shown in Table 3.
Furthermore, as an exploratory analysis, we considered also
the patients who were recruited outside Heidelberg and those
who had already received chemotherapy at the time of blood
collection. The results show a considerable degree of hetero-
geneity, but they all point to an association between longer
telomeres and MM risk (Supporting Information Table 3).
We also performed a meta-analysis with results of a recent
report on LTL and MM risk performed in the EPIC study.
The results of that study clearly suggest an association
between longer LTL and increased risk of MM. We have
meta-analyzed the results form Hosnijeh and ours consider-
ing all the cases together and only the subgroup recruited in
Heidelberg and chemotherapy free at the time of blood col-
lection. The results of the meta-analysis are shown in Sup-
porting Information Table 6. The meta-analysis, as expected,
conﬁrmed the observation that longer telomere are associated
with an increased MM risk.
We found a highly statistically signiﬁcant inverse correla-
tion between age and LTL (beta520.0082; p5 2.21 3
10211).
Possible functional effects
In the Genevar database the rs2242652 SNP is not present.
RegulomeDB showed a score of 5, indicating the possible
presence of a transcription factor binding motif or a DNase
sensitivity peak. HaploReg suggested the presence of DNase
sensitivity peak in several cell types and the possible altera-
tion of nine regulatory motives.
Discussion
With our comprehensive analysis of the TERT and the TERC
loci we have conﬁrmed a recent GWAS signal in TERC and
identiﬁed a novel association between a TERT SNP and MM
risk. In addition we have observed an association between
long LTL and increased MM risk.
We conﬁrmed the association of the minor allele of SNP
TERC-rs10936599 with a decreased risk of MM, providing a
strong evidence of this locus in the disease etiology. We also
genotyped another variant (rs12696304) in the same gene
region, that is in LD with TERC-rs10936599. The two SNPs
are close to each other (10,830 bp) and they are highly corre-
lated (r25 0.82) in our population. Both TERC polymor-
phisms have a functional relevance since they have been
consistently associated with telomere length.35,36,42 However
it is not clear yet whether one of the two variants is the real
etiological cause for MM or if they are both linked to a yet
unknown polymorphic variant.
From a genetic standpoint the most novel ﬁnding of this
study is the association of the minor allele of rs2242652 and
a decreased risk of MM. This polymorphism lies in intron
four of the TERT gene and it is a pleiotropic SNP since it
has been consistently associated with breast, prostate and
skin cancer risk.12,14 As is the case when a tagging approach
is selected, it is difﬁcult to determine whether the
Table 3. Associations between LTL and MM risk
Relative LTL1 Controls/cases OR2 95% CI3 pvalue ptrend
Quartile 1 (0.24–0.78) 125/22 Ref. – – 0.011
Quartile 2 (0.79–0.91) 105/33 1.48 0.78–2.83 0.232
Quartile 3 (0.92–1.09) 119/40 1.14 0.60–2.17 0.680
Quartile 4 (1.09–1.95) 119/45 1.19 0.63–2.24 0.588
1Cases recruited in Heidelberg who were chemotherapy-free at the time of blood collection (N5 140) vs. healthy controls (N5 468).
2OR5 odds ratio, adjusted by age and gender.
395% Confidence interval, adjusted by age and gender.
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polymorphic variant found associated in this study is causal or
is just a disease marker, however there are several clues that
seem to indicate the effective involvement of rs2242652 in can-
cer risk. It lies in a DNase I hypersensitive region, a stretch of
chromatin which is characterized by an intense transcriptional
activity and that is accessible to transcription factors.15 The
results of our analysis using Genevar, RegulomeDB and Hap-
loReg taken together do not convincingly identify a mechanis-
tic link between the SNP and the function of TERT or nearby
genes. However Kote–Jarai et al. have reported that the minor
allele of rs2242652 is associated with a decreased TERT expres-
sion and also that it is predicted to inhibit the binding of sev-
eral transcription factors,15 an observation that would be
consistent with a decreased gene expression. In an independ-
ent study Bojesen et al. found that the minor alleles of
rs2242652 and rs10069690, respectively, increase silencing and
generate a truncated TERT splice variant,12 an observation
that, again, is consistent with a down-regulatory effect of the
polymorphism on the gene expression and activity.
It is difﬁcult to answer the question whether longer or
shorter telomeres are associated with cancer risk since there
is much heterogeneity in the results of association studies.5
In this study we found a weak tendency of MM cases having
longer telomeres than controls, an observation that is in line
with the latest results on other organs. Since it has been
recently shown that differences in sample preparation can
have a large impact on LTL measurements12 we decided to
consider only cases collected in an homogeneous way (i.e.,
recruited locally before chemotherapy). Although we
observed a large degree of heterogeneity according to whether
cases had received chemotherapy before or after blood draw-
ing and according to the origin of cases, all subgroups analy-
ses point to an association between longer telomeres and
MM risk. Considering the small sample size we could use,
our results on LTL should be taken with caution, although if
replicated in independent studies, they could clearly link the
genetic variability of the selected regions to MM risk.
Indeed, both polymorphic variants found in our study are
functional and lie in genes which catalyze de novo addition
of telomeric repeats onto chromosome ends and, therefore, it
seems logical that telomere length might be the connection
between genetic variability and increased MM risk. In partic-
ular a down-regulation of the TERT gene should produce
shorter telomere ends. Our observation that the minor allele
of rs2242652 is associated with decreased MM risk and the
previous reports that it down-regulates TERT expression, and
therefore causes shorter TL, is consistent with our ﬁnding
that longer LTL is, instead, associated with increased MM
risk. Additionally in a very recent manuscript Hosnijeh
et al.39 explored the possible association between LTL and
lymphoma risk in the context of the EPIC study. Among the
cases used in that study there was also a small subgroup of
MM (107 cases). The results found by Hosnijeh et al. are in
complete agreement with what we ﬁnd, namely that longer
telomere are associated with increased MM risk increasing
the strength of our observations. The meta-analysis that we
have performed further corroborates these ﬁndings.
We also found that several polymorphic variants are asso-
ciated with LTL, although considering the correction for mul-
tiple testing none of these associations remained signiﬁcant.
It is however interesting to note that we were able to repli-
cate several known associations between SNPs and LTL, such
as the association of the minor rs10936599 allele with shorter
telomeres, with an estimate almost super-imposable to what
was reported by Codd et al. in a very large study.35 We did
not observe an association for rs2242652 on LTL; however
this effect was seen by Bojesen et al. in a much larger study
than our own.12
We found that the minor allele of TERC-rs12696304 was
associated to a decreased MM risk and with shorter telomere
length. This is consistent with the same observation we made
for TERT-rs2242652, and it is corroborated by similar ﬁnd-
ings from a recent study on colorectal cancer.42
Longer telomeres might be a marker of an actively repro-
ducing cell that has an increased chance of acquiring tumor-
causing mutations.42 The association of genetic variability
and longer telomere could be of a particular importance in
MM since telomerase reactivation and telomerase-mediated
elongation of shorter telomeres is a feature of multiple
myeloma and because there is an ongoing research on a pos-
sible TERT inhibition as a therapeutic approach in MM.42
This study has several limitations, ﬁrst of all we did not
use an array to perform the genotyping and we could not
take into account ancestry informative markers and therefore
we cannot exclude a small proportion of outliers in the popu-
lation. However it is unlikely that a small number of non-
Caucasians would change the results masking a potentially
true association or highlighting a spurious one, as suggested
by the fact that we replicate the ﬁndings by Chubb et al. We
have not included all the polymorphic variants present in the
regions, even though we have a representation, through tag-
ging, of more than 90% of the common genetic variability of
the TERT and TERC loci. Third, DNA for cases and controls
was not extracted from the same starting material since
peripheral blood mononuclear cells were used for cases, while
whole blood was used for controls.
In summary we have replicated a reported genetic suscep-
tibility locus in TERC, we propose a new one in TERT with
an epidemiological and biological explanation, and we
describe the association between longer LTL and MM risk.
Our data suggest the hypothesis of decreased disease risk by
genetic variants that reduce the efﬁciency of the telomerase
complex. This reduced efﬁciency leads to shorter telomere
ends, which in turn are also a marker of decreased MM risk.
Acknowledgements
The authors acknowledge support by the recruiting hospitals and physicians
of the study regions as well as their collaborating nurses and technicians.
They thank Ms. Tanja Maih€ofer, Mr. Manuel Gentiluomo, Ms. Angelika
Stein and Dr. Cosmeri Rizzato (DKFZ, Heidelberg, Germany) for assistance
with lab work.
E
pi
de
m
io
lo
gy
Campa et al. E357
Int. J. Cancer: 136, E351–E358 (2015) VC 2014 UICC
References
1. Raab MS, Podar K, Breitkreutz I, et al. Multiple
myeloma. Lancet 2009;374:324–39.
2. Martino A, Sainz J, Buda G, et al. Genetics and
molecular epidemiology of multiple myeloma: the
rationale for the IMMEnSE consortium (review).
Int J Oncol 2012;40:625–38.
3. Altieri A, Chen B, Bermejo JL, et al. Familial
risks and temporal incidence trends of multiple
myeloma. Eur J Cancer 2006;42:1661–70.
4. Landgren O, Weiss BM. Patterns of monoclonal
gammopathy of undetermined signiﬁcance and
multiple myeloma in various ethnic/racial groups:
support for genetic factors in pathogenesis. Leu-
kemia 2009;23:1691–7.
5. Broderick P, Chubb D, Johnson DC, et al. Com-
mon variation at 3p22.1 and 7p15.3 inﬂuences
multiple myeloma risk. Nat Genet 2012;44:58–61.
6. Campa D, Martino A, Sainz J, et al. Comprehen-
sive investigation of genetic variation in the 8q24
region and multiple myeloma risk in the
IMMEnSE consortium. Br J Haematol 2012;157:
331–8.
7. Chubb D, Weinhold N, Broderick P, et al. Com-
mon variation at 3q26.2, 6p21.33, 17p11.2 and
22q13.1 inﬂuences multiple myeloma risk. Nat
Genet 2013;45:1221–5.
8. Martino A, Campa D, Buda G, et al. Polymor-
phisms in xenobiotic transporters ABCB1,
ABCG2, ABCC2, ABCC1, ABCC3 and multiple
myeloma risk: a case-control study in the context
of the International Multiple Myeloma rESEarch
(IMMEnSE) consortium. Leukemia 2012;26:1419–
22.
9. Martino A, Campa D, Jamroziak K, et al. Impact
of polymorphic variation at 7p15.3, 3p22.1 and
2p23.3 loci on risk of multiple myeloma. Br J
Haematol 2012;158:805–9.
10. Vangsted A, Klausen TW, Vogel U. Genetic var-
iations in multiple myeloma I: effect on risk of
multiple myeloma. Eur J Haematol 2012;88:8–30.
11. Weinhold N, Johnson DC, Chubb D, et al. The
CCND1 c.870G>A polymorphism is a risk factor
for t(11;14)(q13;q32) multiple myeloma. Nat
Genet 2013;45:522–5.
12. Bojesen SE, Pooley KA, Johnatty SE, et al. Multi-
ple independent variants at the TERT locus are
associated with telomere length and risks of
breast and ovarian cancer. Nat Genet 2013;45:
371–84, 84e1–2.
13. Haiman CA, Chen GK, Vachon CM, et al. A
common variant at the TERT-CLPTM1L locus is
associated with estrogen receptor-negative breast
cancer. Nat Genet 2011;43:1210–4.
14. Kote-Jarai Z, Olama AA, Giles GG, et al. Seven
prostate cancer susceptibility loci identiﬁed by a
multi-stage genome-wide association study. Nat
Genet 2011;43:785–91.
15. Kote-Jarai Z, Saunders EJ, Leongamornlert DA,
et al. Fine-mapping identiﬁes multiple prostate
cancer risk loci at 5p15, one of which associates
with TERT expression. Hum Mol Genet 2013;22:
2520–8.
16. McKay JD, Hung RJ, Gaborieau V, et al. Lung
cancer susceptibility locus at 5p15.33. Nat Genet
2008;40:1404–6.
17. Petersen GM, Amundadottir L, Fuchs CS, et al. A
genome-wide association study identiﬁes pancreatic
cancer susceptibility loci on chromosomes 13q22.1,
1q32.1 and 5p15.33. Nat Genet 2010;42:224–8.
18. Rajaraman P, Melin BS, Wang Z, et al. Genome-
wide association study of glioma and meta-analy-
sis. Hum Genet 2012;131:1877–88.
19. Rothman N, Garcia-Closas M, Chatterjee N, et al.
A multi-stage genome-wide association study of
bladder cancer identiﬁes multiple susceptibility
loci. Nat Genet 2010;42:978–84.
20. Turnbull C, Rapley EA, Seal S, et al. Variants
near DMRT1, TERT and ATF7IP are associated
with testicular germ cell cancer. Nat Genet 2010;
42:604–7.
21. Wang Y, Broderick P, Webb E, et al. Common
5p15.33 and 6p21.33 variants inﬂuence lung can-
cer risk. Nat Genet 2008;40:1407–9.
22. Fingerlin TE, Murphy E, Zhang W, et al.
Genome-wide association study identiﬁes multiple
susceptibility loci for pulmonary ﬁbrosis. Nat
Genet 2013;45:613–20.
23. Gudmundsson J, Besenbacher S, Sulem P, et al.
Genetic correction of PSA values using sequence
variants associated with PSA levels. Sci Transl
Med 2010;2:62ra92.
24. Mushiroda T, Wattanapokayakit S, Takahashi A,
et al. A genome-wide association study identiﬁes
an association of a common variant in TERT
with susceptibility to idiopathic pulmonary ﬁbro-
sis. J Med Genet 2008;45:654–6.
25. Blackburn EH. Switching and signaling at the
telomere. Cell 2001;106:661–73.
26. Armanios M. Telomeres and age-related disease:
how telomere biology informs clinical paradigms.
J Clin Investig 2013;123:996–1002.
27. Armanios M, Blackburn EH. The telomere syn-
dromes. Nat Rev Genet 2012;13:693–704.
28. de Lange T. Shelterin: the protein complex that
shapes and safeguards human telomeres. Genes
Dev 2005;19:2100–10.
29. de Lange T. How telomeres solve the end-
protection problem. Science 2009;326:948–52.
30. Martinez P, Blasco MA. Telomeric and extra-
telomeric roles for telomerase and the telomere-
binding proteins. Nat Rev Cancer 2011;11:161–76.
31. McEachern MJ, Krauskopf A, Blackburn EH.
Telomeres and their control. Annu Rev Genet
2000;34:331–58.
32. Blasco MA. Telomeres and human disease: age-
ing, cancer and beyond. Nat Rev Genet 2005;6:
611–22.
33. Wu X, Amos CI, Zhu Y, et al. Telomere dysfunc-
tion: a potential cancer predisposition factor.
J Natl Cancer Inst 2003;95:1211–8.
34. Chung CC, Chanock SJ. Current status of
genome-wide association studies in cancer. Hum
Genet 2011;130:59–78.
35. Codd V, Nelson CP, Albrecht E, et al. Identiﬁca-
tion of seven loci affecting mean telomere length
and their association with disease. Nat Genet
2013;45:422–7, 7e1-2.
36. Nan H, Qureshi AA, Prescott J, et al. Genetic
variants in telomere-maintaining genes and skin
cancer risk. Hum Genet 2011;129:247–53.
37. Roos G, Krober A, Grabowski P, et al. Short telo-
meres are associated with genetic complexity,
high-risk genomic aberrations, and short survival
in chronic lymphocytic leukemia. Blood 2008;111:
2246–52.
38. Willeit P, Willeit J, Mayr A, et al. Telomere
length and risk of incident cancer and cancer
mortality. JAMA 2010;304:69–75.
39. Hosnijeh FS, Matullo G, Russo A, et al. Prediag-
nostic telomere length and risk of B-cell lym-
phoma—results from the EPIC cohort study. Int
J Cancer J Int Cancer 2014; in press.
40. Kimura M, Gazitt Y, Cao X, et al. Synchrony of
telomere length among hematopoietic cells. Exp
Hematol 2010;38:854–9.
41. International Myeloma Working Group. Criteria
for the classiﬁcation of monoclonal
gammopathies, multiple myeloma and related
disorders: a report of the International Myeloma
Working Group. Br J Haematol 2003;121:749–57.
42. Jones AM, Beggs AD, Carvajal-Carmona L, et al.
TERC polymorphisms are associated both with
susceptibility to colorectal cancer and with longer
telomeres. Gut 2012;61:248–54.
43. Cawthon RM. Telomere measurement by quanti-
tative PCR. Nucleic Acids Res 2002;30:e47.
44. Gao X, Starmer J, Martin ER. A multiple testing
correction method for genetic association studies
using correlated single nucleotide polymorphisms.
Genet Epidemiol 2008;32:361–9.
45. Boyle AP, Hong EL, Hariharan M, et al. Annota-
tion of functional variation in personal genomes
using RegulomeDB. Genome Res 2012;22:1790–7.
46. Ward LD, Kellis M. HaploReg: a resource for
exploring chromatin states, conservation, and reg-
ulatory motif alterations within sets of genetically
linked variants. Nucleic Acids Res 2012;40:D930–
4.
47. Grundberg E, Small KS, Hedman AK, et al. Map-
ping cis- and trans-regulatory effects across mul-
tiple tissues in twins. Nat Genet 2012;44:1084–9.
E
pi
de
m
io
lo
gy
E358 Telomerase SNPs, telomere length and myeloma risk
Int. J. Cancer: 136, E351–E358 (2015) VC 2014 UICC
